Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions

Nicholson, Karl G.; Tyrrell, D. A. J.; Harrison, Paul J.; Potter, C. W.; Jennings, R.; Clark, Anthony; Schild, G. C.; Wood, John M.; Yetts, Risha; Seagroatt, Valerie; Huggins, Alan R.; Anderson, Shannon W.

doi:10.1016/s0092-1157(79)80044-x

Cited by 108 publications

(54 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The conclusions from this study are that individuals unprimed for A/USSR/77 virus should be immunized twice to afford a protective level of antibody. This is in agreement with findings in other studies (Feery et al 1979;Nicholson et al 1979;Potter et al 1980). After two doses of A/USSR/77 vaccine, subjects primed for the related A/NJ/76 virus possess a lower degree of protection against A/USSR/77 virus than those unprimed for A/NJ/76 virus.…”

Section: Resultssupporting

confidence: 94%

Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus

Masurel

Ophof

Jong³

1981

J. Hyg.

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 94%

Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus

Masurel

Ophof

Jong³

1981

J. Hyg.

View full text Add to dashboard Cite

“…Whole virus vaccine may induce a more efficient cellular response than split or sub-unit vaccines [29,30] and this may be critical in preventing severe disease and death if not critical for prevention of infection. The candidate VN1203 and IN5/05 vaccines were both effective in inducing TH-1 cell responses (induced by CD4+ T helper cells).…”

Section: Discussionmentioning

confidence: 99%

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses

Kistner

Howard

Spruth

et al. 2007

Vaccine

View full text Add to dashboard Cite

The rapid spread and the transmission to humans of avian influenza virus (H5N1) has induced worldwide fears of a new pandemic and raised concerns over the ability of standard influenza vaccine production methods to rapidly supply sufficient amounts of an effective vaccine. We report here on a robust and flexible strategy which uses wild-type virus grown in a continuous cell culture (Vero) system to produce an inactivated whole virus vaccine. Candidate vaccines based on clade 1 and clade 2 influenza H5N1 strains were developed and demonstrated to be highly immunogenic in animal models. The vaccines induce cross-neutralising antibodies, highly cross-reactive T-cell responses and are protective in a mouse challenge model not only against the homologous virus but against other H5N1 strains, including those from another clade. These data indicate that cell culture-grown, whole virus vaccines, based on the wild-type virus, allow the rapid high yield production of a candidate pandemic vaccine.

show abstract

“…The results obtained for 20 ,ug HA of vaccine were satisfactory, but this was not so for lower doses. In addition , the serum response to the influenza B vaccine were lower than those obtained for comparable doses of influenza A vaccine (Nicholson et al 1979). …”

Section: Discussionmentioning

confidence: 86%

A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection

Goodeve

Potter

Clark

et al. 1983

J. Hyg.

Self Cite

View full text Add to dashboard Cite

SUMMARYOne hundred and nineteen volunteers were divided into five groups, and each volunteer inoculated subcutaneously with an aqueous subunit B/Hong Kong/73 vaccine containing 40, 20, 10, or 5 ,ug of HA or saline alone in a 0-5 ml volume. The incidence of reactions was recorded 24 h after inoculation. One month following immunization the serum HI antibody to B/Hong Kong/73 virus was measured; each volunteer was inoculated intranasally with live, attenuated influenza B (RB77) virus; and the incidence of infection by the challenge virus was determined by HI antibody response.The results showed that the incidence of reactions to all doses of vaccine were relatively low, the severity mild, and the duration short. However, the incidence of reactions was highest for those given 40 jug HA and least for those given 5 4g HA. The serum HI antibody responses to vaccine showed a dose-response relationship. For volunteers given 40 jug HA, 22 (96 %) showed a fourfold rise in antibody titre and all volunteers had antibody titres of > 40 following immunization: for volunteers given 5 ,ug HA the g.m.t. increased from 16-6 to 86-1; and for those given 10 and 20,sg HA the response was intermediate. Following challenge, the lowest incidence ofinfection was seen in volunteers given the highest dose of vaccine. However, all doses of vaccine induced some protection against challenge virus infection, and the incidence of infection was directly related to the serum antibody titre at the time of challenge. The 50 % protection titre of serum HI antibody was estimated as 15 to 20.

show abstract

Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions

Cited by 108 publications

References 11 publications

Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus

Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses

A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection

Contact Info

Product

Resources

About